Veloxis Stock Analysis

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>VEL</div>
Is it time to go long with Veloxis Pharmaceuticals? Veloxis Pharmaceuticals Stock analysis can help investors discover the best opportunities and time the market in virtually any economy. Find the stocks trading at a discount of their intrinsic value will give you an edge in creating a market-bitting portfolio. The current investor indifference towards the small price fluctuations of Veloxis Pharmaceuticals may raise some interest from investors as it closed today at a share price of 0.0 on very low momentum in trading volume. The company directors and management did not add any value to Veloxis Pharmaceuticals investors in March. However, most investors can still diversify their portfolios with Veloxis Pharmaceuticals to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 0.0. The very small Stock volatility is a good signal to investors with longer term investment horizons. Check out World Market Map.
View Stock Analysis For
The Veloxis Pharmaceuticals Stock analysis interface makes it easy to digest most current publicly released information about Veloxis Pharmaceuticals as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. Veloxis stock analysis module also helps to analyze Veloxis Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Veloxis Stock Analysis Notes

The company has Price/Earnings (P/E) ratio of 885.0. Veloxis Pharmaceuticals recorded loss per share of 0.0. The entity had not issued any dividends in recent years. Veloxis Pharmaceuticals AS, a specialty pharmaceutical company, engages in enhancing the lives of transplant patients by identifying, developing, and commercializing products in transplantation. The company was formerly known as LifeCycle Pharma AS and changed its name to Veloxis Pharmaceuticals AS in July 2011. Veloxis Pharmaceuticals operates under Pharmaceuticals And Biosciences classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 58 people. For more information please call the company at 45 70 33 33 00 or visit http://www.veloxis.com.

Veloxis Pharmaceuticals Investment Alerts

Veloxis Pharmaceuticals is not yet fully synchronised with the market data
Veloxis Pharmaceuticals has some characteristics of a very speculative penny stock
Veloxis Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported revenue of 46.49 M. Net Loss for the year was (1.14 M) with profit before overhead, payroll, taxes, and interest of 31.58 M.
VELOXIS PHARMACEU has accumulated about 28.39 M in cash with (8.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.

Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 5.64 B.


The company has Profit Margin (PM) of (2.46) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (4.22) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.04.

Management Efficiency

Veloxis Pharmaceuticals has return on total asset (ROA) of (1.64) % which means that it has lost $1.64 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (26.39) % meaning that it generated substantial loss on money invested by shareholders.

Institutional Stock Holders for Veloxis Pharmaceuticals

Veloxis Pharmaceuticals Technical and Predictive Indicators

Did you try this?

Run World Markets Correlation Now


World Markets Correlation

Find global opportunities by holding instruments from different markets
All  Next Launch Module
Check out World Market Map. Please also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page